{"protocolSection":{"identificationModule":{"nctId":"NCT00294047","orgStudyIdInfo":{"id":"104820"},"secondaryIdInfos":[{"id":"2005-002546-20","type":"EUDRACT_NUMBER"},{"id":"2005","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2005"}],"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older","officialTitle":"A Study to Evaluate Safety, Immunogenicity and Efficacy of GSK Biologicals HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a Three-dose Schedule (0, 1, 6 Month) in Healthy Adult Female Subjects Aged 26 Years and Above"},"statusModule":{"statusVerifiedDate":"2019-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-02-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-01-29","type":"ACTUAL"},"completionDateStruct":{"date":"2014-01-29","type":"ACTUAL"},"studyFirstSubmitDate":"2006-02-17","studyFirstSubmitQcDate":"2006-02-17","studyFirstPostDateStruct":{"date":"2006-02-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-12-08","resultsFirstSubmitQcDate":"2012-02-23","resultsFirstPostDateStruct":{"date":"2012-03-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-12-27","lastUpdatePostDateStruct":{"date":"2020-01-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control. Under Protocol Amendment 3, study participation will last approximately 48 months and involves a total of eleven scheduled visits. Under Protocol Amendment 4, study participation will last up to 84 months and involves a maximum of seventeen scheduled visits.","detailedDescription":"The Protocol Posting has been updated due to protocol amendment 5 and in order to comply with the FDA Amendment Act, Sep 2007."},"conditionsModule":{"conditions":["Infections, Papillomavirus","Papillomavirus Vaccines"],"keywords":["Vaccine","Human papillomavirus","Cervical Cancer","Cervical Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":5752,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cervarix Group","type":"EXPERIMENTAL","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.","interventionNames":["Biological: Cervarix"]},{"label":"Aluminium Hydroxide Group","type":"PLACEBO_COMPARATOR","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.","interventionNames":["Biological: Placebo control"]}],"interventions":[{"type":"BIOLOGICAL","name":"Cervarix","description":"Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.","armGroupLabels":["Cervarix Group"]},{"type":"BIOLOGICAL","name":"Placebo control","description":"Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.","armGroupLabels":["Aluminium Hydroxide Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.","description":"CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nPersistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\n* DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA)\n* Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).","description":"CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\n* DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.","description":"CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Persistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA) - Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).","description":"CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","timeFrame":"Up to Month 84"}],"secondaryOutcomes":[{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\nDetection was done in:\n\n* DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).\n\n* DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.","description":"Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\nOncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nDetection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.\n\nHPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.","description":"Persistent HPV infection (12-month definition) = detection of the same HPV type(s) by PCR in cervical samples at available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).\n\nOncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nsubjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus.\n\nHPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done in:\n\n* DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.\n\nNote: Results for seropositive status were not analysed.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done in:\n\n* DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done on all subjects irrespective of their baseline HPV DNA and serostatus.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done on all subjects irrespective of their baseline HPV DNA status.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection","description":"Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US).\n\nDetection was done in:\n\n* DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.\n\nResults for seropositive status were not analysed.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nDetection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.\n\nHRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy","description":"Detection was done on all subjects irrespective of their baseline HPV DNA status.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With First Colposcopy","description":"Detection was done on all subjects irrespective of their baseline HPV DNA status.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\nCIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done on all subjects irrespective of their baseline HPV DNA and serostatus.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\nDetection was done on all subjects irrespective of their baseline HPV DNA and serostatus.\n\nThe lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)","timeFrame":"Up to Month 48"},{"measure":"Number of Seroconverted Subjects Against HPV-16 in the Immunogenicity Subset.","description":"Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.\n\nHPV-16 assay cut-off value was defined as greater than or equal to 8 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.\n\nImmuno subset=subjects from selected sites N≥1000, at least 250 per region","timeFrame":"At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84"},{"measure":"Number of Seroconverted Subjects Against HPV-18 in the Immunogenicity Subset.","description":"Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.\n\nHPV-18 assay cut-off value was defined as greater than or equal to 7 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.\n\nImmuno subset=subjects from selected sites N≥1000, at least 250 per region","timeFrame":"At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84"},{"measure":"Geometric Mean Concentrations (GMCs) Against HPV-16 Antibody in the Immunogenicity Subset.","description":"GMCs were expressed in ELISA units per milliliter (EL.U/mL).\n\nSeronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.\n\nImmuno subset=subjects from selected sites (N≥1000, at least 250 per region)","timeFrame":"At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84"},{"measure":"Geometric Mean Concentrations (GMCs) Against HPV-18 Antibody in the Immunogenicity Subset.","description":"GMCs were expressed in ELISA units per milliliter (EL.U/mL).\n\nSeronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.\n\nImmuno subset=subjects from selected sites (N≥1000, at least 250 per region)","timeFrame":"At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84"},{"measure":"Number of Seroconverted Subjects Against HPV-16 and HPV-18 Viral Neutralization in a Selected Subset of Subjects.","description":"Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. HPV-16/18 assay cut-off value was defined as greater than or equal to 40 Estimated dose 50% (ED50). Sero- subjects are subjects who had an antibody concentration below 40 ED50 prior to vaccination. Sero+ subjects are subjects who had an antibody concentration equal to or above 50 ED50 prior to vaccination. ED50 = the estimated serum dilution reducing the signal generated by viral infection by 50%","timeFrame":"Prior to vaccination and at Months 7, 12, 18, 24, 48 and 84."},{"measure":"Geometric Mean Titers (GMTs) Against HPV-16 and HPV-18 Viral Neutralization Antibodies in a Selected Subset of Subjects.","description":"Titers are expressed as geometric mean antibody titers (GMTs).\n\nSeronegative (Sero-) subjects are subjects who had an antibody titer below 40 ED50 prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody titer equal to or above 40 ED50 prior to vaccination.\n\nED50 = Estimated dose 50%, the estimated serum dilution reducing the signal generated by viral infection by 50%","timeFrame":"Prior to vaccination and at Months 7, 12, 18, 24, 48 and 84."},{"measure":"Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.","description":"Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).","timeFrame":"Within 7 days (Days 0-6) after vaccination"},{"measure":"Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.","description":"Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = axillary temperature above 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = axillary temperature above 39.0°C.","timeFrame":"Within 7 days (Days 0-6) after vaccination"},{"measure":"Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).","description":"An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 unsolicited AE = an event that prevented normal activity.\n\nA related AE = event assessed by the investigator as causally related to the study vaccination.","timeFrame":"Within 30 days (Days 0 - 29) post-vaccination period."},{"measure":"Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).","description":"SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. A related SAE was defined as an event assessed by the investigator as causally related to the study vaccination.","timeFrame":"Up to Month 48 and up to Month 84"},{"measure":"Number of Subjects Reporting Related or Fatal Serious Adverse Event.","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study.","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\n\nSerious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects Reporting New Onset of Chronic Disease (NOCDs).","description":"NOCDs include autoimmune disorders, asthma and type I diabetes.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects Reporting New Onset of Autoimmune Disease (NOADs).","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects Reporting Medically Significant Conditions (MAEs).","description":"Medically significant conditions were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Pregnancies and Their Outcomes.","description":"Pregnancy outcomes are live infant, premature live infant, elective termination, ectopic pregnancy, spontaneous abortion, lost to follow-up and pregnancy ongoing. For each category it was specified if the infant presents congenital anomaly (CA) or no apparent congenital anomaly (No ACA).","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the Type Assignment Algorithm (TAA)","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done on subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.\n\nTAA: Type assignment algorithm. The lesion was assigned to an HPV type found in the lesion if\n\n1. the same HPV type was found in at least one of the two (closest) preceding cytology samples, or\n2. none of the HPV types found in the lesion were found in any of the two preceding cytology samples (isolate HPV types)","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done in: - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals). - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.","description":"Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. subjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Note: Results for seropositive status were not analysed.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA status.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection","description":"Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US). Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Results for seropositive status were not analysed.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68","timeFrame":"Up to Month 48"},{"measure":"Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy","description":"Detection was done on all subjects irrespective of their baseline HPV DNA status.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With First Colposcopy","description":"Detection was done on all subjects irrespective of their baseline HPV DNA status.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.","timeFrame":"Up to Month 84"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus. The lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)","timeFrame":"Up to Month 84"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* A woman who the investigator believes that she can and will comply with the requirements of the protocol.\n* A women of at least 26 years of age at the time of the first vaccination.\n* Written informed consent obtained from the subject prior to enrolment.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study.\n* Subject must have intact cervix.\n* Subject must have a negative urine pregnancy test. This test is not applicable to women of non-childbearing potential.\n* Subject must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or must be using an effective method of birth control for 30 days prior to the first vaccination and must agree to continue such precautions for two months after completion of the vaccination series.\n\nExclusion criteria:\n\n* Pregnant or breastfeeding (women must be at least three months post-pregnancy and not breastfeeding to enter the study).\n* A women planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the vaccination phase of the study, i.e. up to two months after the last vaccine dose (Month 0 - 8).\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 84).\n* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.\n* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e. days 0 - 29) the first dose of study vaccine. Planned administration/administration of routine vaccines up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window.\n* Previous administration of components of the investigational vaccine\n* Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.\n* History of HPV infection/treatment or planned treatment to evaluate an abnormal cervical cytology (Pap smear) test, e.g. colposcopy.\n* Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination.\n* History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccine.\n* Hypersensitivity to latex.\n* Known acute or chronic, clinically significant neurologic, hepatic or renal functional abnormality, as determined by previous physical examination or laboratory tests.\n* History of chronic condition(s) requiring treatment.\n* Administration of immunoglobulins and/or any blood product within three months preceding the first dose of study vaccine, or planned administration during the study period. Enrolment will be deferred until the subject is outside of specified window.\n* Acute disease at the time of enrolment.\n* Heavy bleeding (menstruation or other) or heavy vaginal discharge in which a pelvic exam cannot be performed (and no cervical sample can be taken). Enrolment will be deferred until condition is resolved according to investigators medical judgement.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"26 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"GSK Investigational Site","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"GSK Investigational Site","city":"Golden","state":"Colorado","zip":"80401","country":"United States","geoPoint":{"lat":39.75554,"lon":-105.2211}},{"facility":"GSK Investigational Site","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"GSK Investigational Site","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"GSK Investigational Site","city":"Augusta","state":"Georgia","zip":"30912","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"GSK Investigational Site","city":"Iowa City","state":"Iowa","zip":"52242","country":"United States","geoPoint":{"lat":41.66113,"lon":-91.53017}},{"facility":"GSK Investigational Site","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"GSK Investigational Site","city":"Bardstown","state":"Kentucky","zip":"40004","country":"United States","geoPoint":{"lat":37.80923,"lon":-85.4669}},{"facility":"GSK Investigational Site","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"GSK Investigational Site","city":"Chaska","state":"Minnesota","zip":"55318","country":"United States","geoPoint":{"lat":44.78941,"lon":-93.60218}},{"facility":"GSK Investigational Site","city":"Omaha","state":"Nebraska","zip":"68131","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"GSK Investigational Site","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}},{"facility":"GSK Investigational Site","city":"Albuquerque","state":"New Mexico","zip":"87131","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"GSK Investigational Site","city":"Syracuse","state":"New York","zip":"13057","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"facility":"GSK Investigational Site","city":"Chapel Hill","state":"North Carolina","zip":"27514","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"GSK Investigational Site","city":"New Bern","state":"North Carolina","zip":"28562","country":"United States","geoPoint":{"lat":35.10849,"lon":-77.04411}},{"facility":"GSK Investigational Site","city":"Akron","state":"Ohio","zip":"44311","country":"United States","geoPoint":{"lat":41.08144,"lon":-81.51901}},{"facility":"GSK Investigational Site","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"GSK Investigational Site","city":"Tulsa","state":"Oklahoma","zip":"74105","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"GSK Investigational Site","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"GSK Investigational Site","city":"Carnegie","state":"Pennsylvania","zip":"15106","country":"United States","geoPoint":{"lat":40.40868,"lon":-80.08339}},{"facility":"GSK Investigational Site","city":"Erie","state":"Pennsylvania","zip":"16507","country":"United States","geoPoint":{"lat":42.12922,"lon":-80.08506}},{"facility":"GSK Investigational Site","city":"Erie","state":"Pennsylvania","zip":"16508","country":"United States","geoPoint":{"lat":42.12922,"lon":-80.08506}},{"facility":"GSK Investigational Site","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"GSK Investigational Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"GSK Investigational Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15236","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"GSK Investigational Site","city":"Wexford","state":"Pennsylvania","zip":"15090","country":"United States","geoPoint":{"lat":40.62646,"lon":-80.05589}},{"facility":"GSK Investigational Site","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"GSK Investigational Site","city":"Houston","state":"Texas","zip":"77004","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"GSK Investigational Site","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"GSK Investigational Site","city":"Salt Lake City","state":"Utah","zip":"84109","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"GSK Investigational Site","city":"Salt Lake City","state":"Utah","zip":"84121","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"GSK Investigational Site","city":"South Jordan","state":"Utah","zip":"84095","country":"United States","geoPoint":{"lat":40.56217,"lon":-111.92966}},{"facility":"GSK Investigational Site","city":"Wenatchee","state":"Washington","zip":"98801","country":"United States","geoPoint":{"lat":47.42346,"lon":-120.31035}},{"facility":"GSK Investigational Site","city":"La Crosse","state":"Wisconsin","zip":"54601","country":"United States","geoPoint":{"lat":43.80136,"lon":-91.23958}},{"facility":"GSK Investigational Site","city":"Parkville","state":"Victoria","zip":"3052","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"GSK Investigational Site","city":"Perth","state":"Western Australia","country":"Australia","geoPoint":{"lat":-31.95224,"lon":115.8614}},{"facility":"GSK Investigational Site","city":"Edmonton","state":"Alberta","zip":"T6G 2C8","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"GSK Investigational Site","city":"Vancouver","state":"British Columbia","zip":"V6H 3N1","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"GSK Investigational Site","city":"Halifax","state":"Nova Scotia","zip":"B3H 2Y9","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"GSK Investigational Site","city":"Truro","state":"Nova Scotia","zip":"B2N 1L2","country":"Canada","geoPoint":{"lat":45.36685,"lon":-63.26538}},{"facility":"GSK Investigational Site","city":"Waterloo","state":"Ontario","zip":"N2L 6H6","country":"Canada","geoPoint":{"lat":43.4668,"lon":-80.51639}},{"facility":"GSK Investigational Site","city":"Québec","state":"Quebec","zip":"G1S 2L6","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"GSK Investigational Site","city":"Sherbrooke","state":"Quebec","zip":"J1H 1Z1","country":"Canada","geoPoint":{"lat":45.40008,"lon":-71.89908}},{"facility":"GSK Investigational Site","city":"Cuenavaca","state":"Morelos","zip":"62430","country":"Mexico"},{"facility":"GSK Investigational Site","city":"Jojutla / Morelos","country":"Mexico"},{"facility":"GSK Investigational Site","city":"Amsterdam","zip":"1007 MB","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"GSK Investigational Site","city":"Delft","zip":"2625 AD","country":"Netherlands","geoPoint":{"lat":52.00667,"lon":4.35556}},{"facility":"GSK Investigational Site","city":"Rotterdam","zip":"3015 CE","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"GSK Investigational Site","city":"Lima","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"GSK Investigational Site","city":"Laguna","country":"Philippines","geoPoint":{"lat":12.31667,"lon":123.7}},{"facility":"GSK Investigational Site","city":"San Pablo","country":"Philippines","geoPoint":{"lat":14.0683,"lon":121.3256}},{"facility":"GSK Investigational Site","city":"Taft Avenue, Manila","zip":"1700","country":"Philippines","geoPoint":{"lat":14.6042,"lon":120.9822}},{"facility":"GSK Investigational Site","city":"Almada","zip":"2805-267 Almada","country":"Portugal","geoPoint":{"lat":38.67902,"lon":-9.1569}},{"facility":"GSK Investigational Site","city":"Coimbra","zip":"3000-075 Coimbra","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"GSK Investigational Site","city":"Lisbon","zip":"1200-831 Lisboa","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"GSK Investigational Site","city":"Porto","zip":"4200-023 Porto","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"GSK Investigational Site","city":"Setúbal","zip":"2910-446 Setúbal","country":"Portugal","geoPoint":{"lat":38.5244,"lon":-8.8882}},{"facility":"GSK Investigational Site","city":"Moscow","zip":"109263","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"GSK Investigational Site","city":"Moscow","zip":"115 478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"GSK Investigational Site","city":"Moscow","zip":"117997","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"GSK Investigational Site","city":"Saint Petersburg","zip":"190020","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"GSK Investigational Site","city":"Saint Petersburg","zip":"199034","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"GSK Investigational Site","city":"Yekaterinburg","zip":"620073","country":"Russia","geoPoint":{"lat":56.85733,"lon":60.61529}},{"facility":"GSK Investigational Site","city":"Singapore","zip":"119074","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"GSK Investigational Site","city":"Singapore","zip":"229899","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"GSK Investigational Site","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"GSK Investigational Site","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"GSK Investigational Site","city":"Northwood","state":"Middlesex","zip":"HA6 2RN","country":"United Kingdom","geoPoint":{"lat":51.61162,"lon":-0.42454}},{"facility":"GSK Investigational Site","city":"Aberdeen","zip":"AB25 7ZD","country":"United Kingdom","geoPoint":{"lat":57.14369,"lon":-2.09814}},{"facility":"GSK Investigational Site","city":"Cardiff","zip":"CF14 4XN","country":"United Kingdom","geoPoint":{"lat":51.48,"lon":-3.18}},{"facility":"GSK Investigational Site","city":"Gateshead","zip":"NE9 6SX","country":"United Kingdom","geoPoint":{"lat":54.96209,"lon":-1.60168}},{"facility":"GSK Investigational Site","city":"London","zip":"EC1M 6BQ","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"GSK Investigational Site","city":"Manchester","zip":"M13 9WL","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"referencesModule":{"references":[{"pmid":"19221517","type":"BACKGROUND","citation":"Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009 May;5(5):332-40. doi: 10.4161/hv.5.5.7211. Epub 2009 May 20."},{"pmid":"25189358","type":"BACKGROUND","citation":"Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmeron J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Levin MJ, Chatterjee A, Stapleton JT, Martens M, Quint W, David MP, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G; VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014 Dec 20;384(9961):2213-27. doi: 10.1016/S0140-6736(14)60920-X. Epub 2014 Sep 1."},{"pmid":"18845199","type":"BACKGROUND","citation":"Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008 Dec 2;26(51):6630-8. doi: 10.1016/j.vaccine.2008.09.049."},{"pmid":"27373900","type":"BACKGROUND","citation":"Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmeron J, McNeil S, Stapleton JT, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, Ter Harmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YKT, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WGV, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F; VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016 Oct;16(10):1154-1168. doi: 10.1016/S1473-3099(16)30120-7. Epub 2016 Jun 28."},{"pmid":"27998562","type":"BACKGROUND","citation":"Wheeler CM, Struyf F; HPV-015 study group. The safety of Cervarix? - Authors' reply. Lancet Infect Dis. 2017 Jan;17(1):20-21. doi: 10.1016/S1473-3099(16)30540-0. No abstract available."},{"pmid":"41276263","type":"DERIVED","citation":"Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, Petkovic J, Villanueva G, Morrison J. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2."},{"pmid":"31824976","type":"DERIVED","citation":"Chen J, Gopala K, Akarsh PK, Struyf F, Rosillon D. Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine. Open Forum Infect Dis. 2019 Dec 4;6(12):ofz486. doi: 10.1093/ofid/ofz486. eCollection 2019 Dec."},{"pmid":"31273942","type":"DERIVED","citation":"Rosillon D, Baril L, Del Rosario-Raymundo MR, Wheeler CM, Skinner SR, Garland SM, Salmeron J, Lazcano-Ponce E, Vallejos CS, Stoney T, Ter Harmsel B, Lim TYK, Quek SC, Minkina G, McNeil SA, Bouchard C, Fong KL, Money D, Ilancheran A, Savicheva A, Cruickshank M, Chatterjee A, Fiander A, Martens M, Bozonnat MC, Struyf F, Dubin G, Castellsague X. Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies. Cancer Med. 2019 Aug;8(10):4938-4953. doi: 10.1002/cam4.1879. Epub 2019 Jul 5."},{"pmid":"26685704","type":"DERIVED","citation":"Skinner SR, Wheeler CM, Romanowski B, Castellsague X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L; VIVIANE Study Group. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer. 2016 May 15;138(10):2428-38. doi: 10.1002/ijc.29971."}],"seeAlsoLinks":[{"label":"Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.","url":"https://www.clinicalstudydatarequest.com"}],"availIpds":[{"id":"104820","type":"Informed Consent Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"104820","type":"Clinical Study Report","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"104820","type":"Study Protocol","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"104820","type":"Dataset Specification","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"104820","type":"Individual Participant Data Set","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"104820","type":"Statistical Analysis Plan","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"IPD is available via the Clinical Study Data Request site (click on the link provided below)","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"IPD is available via the Clinical Study Data Request site (click on the link provided below)","accessCriteria":"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.","url":"https://clinicalstudydatarequest.com/Posting.aspx?ID=1517"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Enrolment was stratified by (1) age, with the majority of subjects in age strata 26 - 35 years and 36 - 45 years (about 45% each) and about 10% in the age stratum 46+ years, and (2) previous HPV history (in each age stratum, the number of women with a history of HPV infection/treatment was limited to approximately 15%).","recruitmentDetails":"Some subjects completed the study at Months 36 and 48 as they did not want to participate to the extensions up to Month 84, but they were included in the safety analysis for these subsequent timepoints.","groups":[{"id":"FG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"FG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"periods":[{"title":"Month 48","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2881"},{"groupId":"FG001","numSubjects":"2871"}]},{"type":"Participated up to Month 48","achievements":[{"groupId":"FG000","numSubjects":"2305"},{"groupId":"FG001","numSubjects":"2281"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2456"},{"groupId":"FG001","numSubjects":"2438"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"425"},{"groupId":"FG001","numSubjects":"433"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"111"},{"groupId":"FG001","numSubjects":"115"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"272"},{"groupId":"FG001","numSubjects":"287"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"14"}]}]},{"title":"Month 84","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2877"},{"groupId":"FG001","numSubjects":"2870"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"The number of subjects who remained up to Month 48 in the Cervarix Group = 2146","numSubjects":"1904"},{"groupId":"FG001","comment":"The number of subjects who remained up to Month 48 in the Aluminium Hydroxide Group = 2116","numSubjects":"1881"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"973"},{"groupId":"FG001","numSubjects":"989"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"31"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"187"},{"groupId":"FG001","numSubjects":"190"}]},{"type":"Absent Cervix","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Work related reasons","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Center closed, subject did not transfer","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Family problems","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lack of time","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Personal reason","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Subject does not want male physician","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Transport reimbursement delayed","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Unable to reach study site","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Under investigation locally","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Visit missed","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"No consent for Month 84 Follow-up","reasons":[{"groupId":"FG000","numSubjects":"731"},{"groupId":"FG001","numSubjects":"754"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"BG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2881"},{"groupId":"BG001","value":"2871"},{"groupId":"BG002","value":"5752"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37.0","spread":"7.24"},{"groupId":"BG001","value":"37.0","spread":"7.32"},{"groupId":"BG002","value":"37.0","spread":"7.28"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2881"},{"groupId":"BG001","value":"2871"},{"groupId":"BG002","value":"5752"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.","description":"CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nPersistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\n* DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA)\n* Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1898"},{"groupId":"OG001","value":"1854"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"36"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1545"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"27"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1597"},{"groupId":"OG001","value":"1571"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"900"},{"groupId":"OG001","value":"864"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"14"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"605"},{"groupId":"OG001","value":"594"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"574"},{"groupId":"OG001","value":"550"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"51"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2167"},{"groupId":"OG001","value":"2131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"36"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2203"},{"groupId":"OG001","value":"2165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).","description":"CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\n* DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1898"},{"groupId":"OG001","value":"1854"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"36"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1545"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"27"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1597"},{"groupId":"OG001","value":"1571"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"900"},{"groupId":"OG001","value":"864"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"605"},{"groupId":"OG001","value":"594"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"574"},{"groupId":"OG001","value":"550"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"49"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2167"},{"groupId":"OG001","value":"2131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"35"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2203"},{"groupId":"OG001","value":"2165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.","description":"CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Persistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA) - Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2147"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1852"},{"groupId":"OG001","value":"1818"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"71"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1507"},{"groupId":"OG001","value":"1491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"53"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1565"},{"groupId":"OG001","value":"1541"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"20"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"870"},{"groupId":"OG001","value":"849"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"588"},{"groupId":"OG001","value":"584"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"552"},{"groupId":"OG001","value":"540"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"90"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2112"},{"groupId":"OG001","value":"2091"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"63"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2149"},{"groupId":"OG001","value":"2123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"29"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).","description":"CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2147"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1852"},{"groupId":"OG001","value":"1818"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"71"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1507"},{"groupId":"OG001","value":"1491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"53"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1565"},{"groupId":"OG001","value":"1541"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"20"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"870"},{"groupId":"OG001","value":"849"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"588"},{"groupId":"OG001","value":"584"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"552"},{"groupId":"OG001","value":"540"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"88"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2112"},{"groupId":"OG001","value":"2091"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"62"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2149"},{"groupId":"OG001","value":"2123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"28"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\nDetection was done in:\n\n* DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2178"},{"groupId":"OG001","value":"2152"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1859"},{"groupId":"OG001","value":"1822"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"34"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1518"},{"groupId":"OG001","value":"1495"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"26"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1566"},{"groupId":"OG001","value":"1542"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"880"},{"groupId":"OG001","value":"851"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"591"},{"groupId":"OG001","value":"583"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"543"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2178"},{"groupId":"OG001","value":"2152"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"45"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2126"},{"groupId":"OG001","value":"2094"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"34"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2160"},{"groupId":"OG001","value":"2127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).\n\n* DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2146"},{"groupId":"OG001","value":"2124"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1832"},{"groupId":"OG001","value":"1800"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"18"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1499"},{"groupId":"OG001","value":"1476"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1543"},{"groupId":"OG001","value":"1525"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"864"},{"groupId":"OG001","value":"839"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"579"},{"groupId":"OG001","value":"577"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"553"},{"groupId":"OG001","value":"532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2146"},{"groupId":"OG001","value":"2124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"21"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2095"},{"groupId":"OG001","value":"2069"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"14"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2128"},{"groupId":"OG001","value":"2099"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.","description":"Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\nOncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nDetection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.\n\nHPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2179"},{"groupId":"OG001","value":"2154"}]}],"classes":[{"title":"HPV-16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2126"},{"groupId":"OG001","value":"2094"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"34"}]}]},{"title":"HPV-18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2160"},{"groupId":"OG001","value":"2127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}]},{"title":"HPV-31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2126"},{"groupId":"OG001","value":"2132"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"19"}]}]},{"title":"HPV-33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2158"},{"groupId":"OG001","value":"2136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"}]}]},{"title":"HPV-35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2165"},{"groupId":"OG001","value":"2144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"}]}]},{"title":"HPV-39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2150"},{"groupId":"OG001","value":"2119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"11"}]}]},{"title":"HPV-45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2160"},{"groupId":"OG001","value":"2130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"17"}]}]},{"title":"HPV-51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2125"},{"groupId":"OG001","value":"2113"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"26"}]}]},{"title":"HPV-52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2113"},{"groupId":"OG001","value":"2101"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"38"}]}]},{"title":"HPV-56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2154"},{"groupId":"OG001","value":"2123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"20"}]}]},{"title":"HPV-58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2152"},{"groupId":"OG001","value":"2135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2158"},{"groupId":"OG001","value":"2126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}]},{"title":"HPV-66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2141"},{"groupId":"OG001","value":"2122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"}]}]},{"title":"HPV-68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2138"},{"groupId":"OG001","value":"2128"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"23"}]}]},{"title":"HPV-31/45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2175"},{"groupId":"OG001","value":"2152"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"35"}]}]},{"title":"HPV-31/45/33/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2179"},{"groupId":"OG001","value":"2154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"83"}]}]},{"title":"HPV-39/45/59/68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2179"},{"groupId":"OG001","value":"2154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"60"}]}]},{"title":"HPV-31/33/35/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2179"},{"groupId":"OG001","value":"2154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"80"}]}]},{"title":"HPV-31/45/33/52/58/35/39/51/56/59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2179"},{"groupId":"OG001","value":"2154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"146"}]}]},{"title":"HPV-HRW","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2179"},{"groupId":"OG001","value":"2154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"185"}]}]},{"title":"HPV-HR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2179"},{"groupId":"OG001","value":"2154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"217"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.","description":"Persistent HPV infection (12-month definition) = detection of the same HPV type(s) by PCR in cervical samples at available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).\n\nOncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nsubjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus.\n\nHPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2147"},{"groupId":"OG001","value":"2126"}]}],"classes":[{"title":"HPV-16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2095"},{"groupId":"OG001","value":"2069"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"14"}]}]},{"title":"HPV-18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2128"},{"groupId":"OG001","value":"2099"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}]},{"title":"HPV-31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2096"},{"groupId":"OG001","value":"2104"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2126"},{"groupId":"OG001","value":"2110"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2133"},{"groupId":"OG001","value":"2116"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2119"},{"groupId":"OG001","value":"2091"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2129"},{"groupId":"OG001","value":"2102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2093"},{"groupId":"OG001","value":"2086"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"14"}]}]},{"title":"HPV-52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2081"},{"groupId":"OG001","value":"2074"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"23"}]}]},{"title":"HPV-56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2124"},{"groupId":"OG001","value":"2096"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2120"},{"groupId":"OG001","value":"2108"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}]},{"title":"HPV-59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2126"},{"groupId":"OG001","value":"2098"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2109"},{"groupId":"OG001","value":"2094"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2106"},{"groupId":"OG001","value":"2100"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"13"}]}]},{"title":"HPV-31/45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2144"},{"groupId":"OG001","value":"2124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"17"}]}]},{"title":"HPV-31/45/33/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2147"},{"groupId":"OG001","value":"2126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"49"}]}]},{"title":"HPV-39/45/59/68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2147"},{"groupId":"OG001","value":"2126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"29"}]}]},{"title":"HPV-31/33/35/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2147"},{"groupId":"OG001","value":"2126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"51"}]}]},{"title":"HPV-31/45/33/52/58/35/39/51/56/59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2147"},{"groupId":"OG001","value":"2126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"84"}]}]},{"title":"HPV-HRW","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2147"},{"groupId":"OG001","value":"2126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"105"}]}]},{"title":"HPV-HR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2147"},{"groupId":"OG001","value":"2126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"122"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done in:\n\n* DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.\n\nNote: Results for seropositive status were not analysed.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1898"},{"groupId":"OG001","value":"1854"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1545"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1597"},{"groupId":"OG001","value":"1571"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2167"},{"groupId":"OG001","value":"2131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2203"},{"groupId":"OG001","value":"2165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done in:\n\n* DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1898"},{"groupId":"OG001","value":"1854"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1545"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1597"},{"groupId":"OG001","value":"1571"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"900"},{"groupId":"OG001","value":"864"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"605"},{"groupId":"OG001","value":"594"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"574"},{"groupId":"OG001","value":"550"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"11"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2167"},{"groupId":"OG001","value":"2131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2203"},{"groupId":"OG001","value":"2165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done on all subjects irrespective of their baseline HPV DNA and serostatus.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2740"},{"groupId":"OG001","value":"2737"}]}],"classes":[{"title":"HPV-16/18","categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"56"}]}]},{"title":"HPV-16","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"42"}]}]},{"title":"HPV-18","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"20"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done on all subjects irrespective of their baseline HPV DNA status.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2740"},{"groupId":"OG001","value":"2737"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"178"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection","description":"Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US).\n\nDetection was done in:\n\n* DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).\n* Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.\n\nResults for seropositive status were not analysed.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1898"},{"groupId":"OG001","value":"1854"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"31"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1545"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"24"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1597"},{"groupId":"OG001","value":"1571"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"38"}]}]},{"title":"HPV-16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2167"},{"groupId":"OG001","value":"2131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"27"}]}]},{"title":"HPV-18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2203"},{"groupId":"OG001","value":"2165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nDetection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.\n\nHRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2225"},{"groupId":"OG001","value":"2192"}]}],"classes":[{"title":"HPV-16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2167"},{"groupId":"OG001","value":"2131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"27"}]}]},{"title":"HPV-18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2203"},{"groupId":"OG001","value":"2165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"}]}]},{"title":"HPV-31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2172"},{"groupId":"OG001","value":"2170"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"}]}]},{"title":"HPV-33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2204"},{"groupId":"OG001","value":"2173"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2211"},{"groupId":"OG001","value":"2181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2196"},{"groupId":"OG001","value":"2156"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"}]}]},{"title":"HPV-45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2206"},{"groupId":"OG001","value":"2168"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"17"}]}]},{"title":"HPV-51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2171"},{"groupId":"OG001","value":"2149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"}]}]},{"title":"HPV-52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2158"},{"groupId":"OG001","value":"2139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"}]}]},{"title":"HPV-56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2200"},{"groupId":"OG001","value":"2158"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"19"}]}]},{"title":"HPV-58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2198"},{"groupId":"OG001","value":"2172"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"}]}]},{"title":"HPV-59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2202"},{"groupId":"OG001","value":"2164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"15"}]}]},{"title":"HPV-66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2187"},{"groupId":"OG001","value":"2160"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"26"}]}]},{"title":"HPV-68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2184"},{"groupId":"OG001","value":"2164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-31/45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2221"},{"groupId":"OG001","value":"2190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"28"}]}]},{"title":"HPV-31/45/33/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2225"},{"groupId":"OG001","value":"2192"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"54"}]}]},{"title":"HPV-39/45/59/68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2225"},{"groupId":"OG001","value":"2192"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"48"}]}]},{"title":"HPV-31/33/35/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2225"},{"groupId":"OG001","value":"2192"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"49"}]}]},{"title":"HPV-31/45/33/52/58/35/39/51/56/59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2225"},{"groupId":"OG001","value":"2192"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"107"}]}]},{"title":"HPV-HRW","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2225"},{"groupId":"OG001","value":"2192"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"126"}]}]},{"title":"HPV-HR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2225"},{"groupId":"OG001","value":"2192"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"148"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy","description":"Detection was done on all subjects irrespective of their baseline HPV DNA status.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2740"},{"groupId":"OG001","value":"2737"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With First Colposcopy","description":"Detection was done on all subjects irrespective of their baseline HPV DNA status.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2741"},{"groupId":"OG001","value":"2738"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"422"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\nCIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done on all subjects irrespective of their baseline HPV DNA and serostatus.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2772"},{"groupId":"OG001","value":"2779"}]}],"classes":[{"title":"HPV-16/18","categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"158"}]}]},{"title":"HPV-16","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"118"}]}]},{"title":"HPV-18","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"52"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.\n\nDetection was done on all subjects irrespective of their baseline HPV DNA and serostatus.\n\nThe lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2772"},{"groupId":"OG001","value":"2779"}]}],"classes":[{"title":"HPV-16/18","categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"155"}]}]},{"title":"HPV-16","categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"117"}]}]},{"title":"HPV-18","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"49"}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted Subjects Against HPV-16 in the Immunogenicity Subset.","description":"Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.\n\nHPV-16 assay cut-off value was defined as greater than or equal to 8 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.\n\nImmuno subset=subjects from selected sites N≥1000, at least 250 per region","populationDescription":"The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"374"}]}],"classes":[{"title":"Sero- before vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"374"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Sero- at Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"371"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"13"}]}]},{"title":"Sero- at Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"349"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"28"}]}]},{"title":"Sero- at Month 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"9"}]}]},{"title":"Sero- at Month 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"350"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"11"}]}]},{"title":"Sero- at Month 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"320"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"23"}]}]},{"title":"Sero- at Month 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"},{"groupId":"OG001","value":"316"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"345"},{"groupId":"OG001","value":"31"}]}]},{"title":"Sero- at Month 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"251"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"11"}]}]},{"title":"Sero- at Month 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"5"}]}]},{"title":"Sero- at Month 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"255"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"2"}]}]},{"title":"Sero+ before vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"179"}]}]},{"title":"Sero+ at Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"166"}]}]},{"title":"Sero+ at Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"158"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"151"}]}]},{"title":"Sero+ at Month 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"144"}]}]},{"title":"Sero+ at Month 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"136"}]}]},{"title":"Sero+ at Month 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"131"}]}]},{"title":"Sero+ at Month 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"135"}]}]},{"title":"Sero+ at Month 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"95"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"79"}]}]},{"title":"Sero+ at Month 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"57"}]}]},{"title":"Sero+ at Month 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"101"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"51"}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted Subjects Against HPV-18 in the Immunogenicity Subset.","description":"Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.\n\nHPV-18 assay cut-off value was defined as greater than or equal to 7 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.\n\nImmuno subset=subjects from selected sites N≥1000, at least 250 per region","populationDescription":"The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"379"}]}],"classes":[{"title":"Sero- before vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"379"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Sero- at Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"374"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"12"}]}]},{"title":"Sero- at Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"352"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"16"}]}]},{"title":"Sero- at Month 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"347"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"12"}]}]},{"title":"Sero- at Month 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"358"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"14"}]}]},{"title":"Sero- at Month 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"346"},{"groupId":"OG001","value":"14"}]}]},{"title":"Sero- at Month 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"320"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"336"},{"groupId":"OG001","value":"16"}]}]},{"title":"Sero- at Month 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"246"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"11"}]}]},{"title":"Sero- at Month 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"254"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"3"}]}]},{"title":"Sero- at month 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"257"},{"groupId":"OG001","value":"3"}]}]},{"title":"Sero+ before vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"164"}]}]},{"title":"Sero+ at Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"161"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"146"}]}]},{"title":"Sero+ at Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"133"}]}]},{"title":"Sero+ at Month 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"118"}]}]},{"title":"Sero+ at Month 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"114"}]}]},{"title":"Sero+ at Month 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"92"}]}]},{"title":"Sero+ at Month 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"94"}]}]},{"title":"Sero+ at Month 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"91"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"58"}]}]},{"title":"Sero+ at Month 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"99"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"32"}]}]},{"title":"Sero+ at Month 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"98"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"32"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations (GMCs) Against HPV-16 Antibody in the Immunogenicity Subset.","description":"GMCs were expressed in ELISA units per milliliter (EL.U/mL).\n\nSeronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.\n\nImmuno subset=subjects from selected sites (N≥1000, at least 250 per region)","populationDescription":"The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EL.U/mL","timeFrame":"At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"374"}]}],"classes":[{"title":"Sero-before vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"374"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody concentration equal to or above the assay cut-off value."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody concentration equal to or above the assay cut-off value."}]}]},{"title":"Sero- at Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"371"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5412.9","lowerLimit":"4934.3","upperLimit":"5938.0"},{"groupId":"OG001","value":"4.3","lowerLimit":"4.1","upperLimit":"4.4"}]}]},{"title":"Sero- at Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"349"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1542.5","lowerLimit":"1393.2","upperLimit":"1707.8"},{"groupId":"OG001","value":"4.4","lowerLimit":"4.2","upperLimit":"4.5"}]}]},{"title":"Sero- at Month 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"992.6","lowerLimit":"893.9","upperLimit":"1102.2"},{"groupId":"OG001","value":"4.1","lowerLimit":"4.0","upperLimit":"4.2"}]}]},{"title":"Sero- at Month 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"350"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"827.8","lowerLimit":"745.2","upperLimit":"919.5"},{"groupId":"OG001","value":"4.2","lowerLimit":"4.1","upperLimit":"4.4"}]}]},{"title":"Sero- at Month 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"320"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"612.9","lowerLimit":"550.1","upperLimit":"682.8"},{"groupId":"OG001","value":"4.5","lowerLimit":"4.2","upperLimit":"4.7"}]}]},{"title":"Sero- at Month 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"},{"groupId":"OG001","value":"316"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"546.2","lowerLimit":"490.4","upperLimit":"608.2"},{"groupId":"OG001","value":"4.6","lowerLimit":"4.4","upperLimit":"4.9"}]}]},{"title":"Sero- at Month 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"251"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"447.1","lowerLimit":"394.3","upperLimit":"507.0"},{"groupId":"OG001","value":"4.3","lowerLimit":"4.1","upperLimit":"4.5"}]}]},{"title":"Sero- at Month 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"412.8","lowerLimit":"364.0","upperLimit":"468.1"},{"groupId":"OG001","value":"9.8","lowerLimit":"9.5","upperLimit":"10.0"}]}]},{"title":"Sero- at Month 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"255"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"381.0","lowerLimit":"334.7","upperLimit":"433.8"},{"groupId":"OG001","value":"9.6","lowerLimit":"9.4","upperLimit":"9.9"}]}]},{"title":"Sero+ before vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","lowerLimit":"33.6","upperLimit":"45.9"},{"groupId":"OG001","value":"38.6","lowerLimit":"33.2","upperLimit":"44.9"}]}]},{"title":"Sero+ at Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5845.5","lowerLimit":"5113.8","upperLimit":"6682.0"},{"groupId":"OG001","value":"33.4","lowerLimit":"28.2","upperLimit":"39.5"}]}]},{"title":"Sero+ at month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"158"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2705.8","lowerLimit":"2313.2","upperLimit":"3165.1"},{"groupId":"OG001","value":"38.0","lowerLimit":"32.0","upperLimit":"45.3"}]}]},{"title":"Sero+ at Month 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2104.7","lowerLimit":"1780.5","upperLimit":"2487.8"},{"groupId":"OG001","value":"30.5","lowerLimit":"25.2","upperLimit":"36.9"}]}]},{"title":"Sero+ at Month 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1883.5","lowerLimit":"1599.4","upperLimit":"2218.1"},{"groupId":"OG001","value":"29.6","lowerLimit":"24.5","upperLimit":"35.7"}]}]},{"title":"Sero+ at month 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1363.8","lowerLimit":"1138.2","upperLimit":"1634.2"},{"groupId":"OG001","value":"30.6","lowerLimit":"25.3","upperLimit":"37.0"}]}]},{"title":"Sero+ at Month 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1261.2","lowerLimit":"1048.4","upperLimit":"1517.1"},{"groupId":"OG001","value":"34.3","lowerLimit":"28.8","upperLimit":"40.8"}]}]},{"title":"Sero+ at Month 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"95"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"943.0","lowerLimit":"749.2","upperLimit":"1187.0"},{"groupId":"OG001","value":"24.7","lowerLimit":"19.2","upperLimit":"31.7"}]}]},{"title":"Sero+ at Month 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1053.7","lowerLimit":"841.0","upperLimit":"1320.3"},{"groupId":"OG001","value":"25.6","lowerLimit":"20.7","upperLimit":"31.5"}]}]},{"title":"Sero+ at Month 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"101"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"954.3","lowerLimit":"755.3","upperLimit":"1205.8"},{"groupId":"OG001","value":"23.9","lowerLimit":"19.3","upperLimit":"29.5"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations (GMCs) Against HPV-18 Antibody in the Immunogenicity Subset.","description":"GMCs were expressed in ELISA units per milliliter (EL.U/mL).\n\nSeronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.\n\nImmuno subset=subjects from selected sites (N≥1000, at least 250 per region)","populationDescription":"The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EL.U/mL","timeFrame":"At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"379"}]}],"classes":[{"title":"Sero- before vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"379"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-18 antibody concentration equal to or above the assay cut-off value."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-18 antibody concentration equal to or above the assay cut-off value."}]}]},{"title":"Sero- at Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"374"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2567.7","lowerLimit":"2339.5","upperLimit":"2818.2"},{"groupId":"OG001","value":"3.7","lowerLimit":"3.6","upperLimit":"3.9"}]}]},{"title":"Sero- at Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"352"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"645.3","lowerLimit":"576.6","upperLimit":"722.1"},{"groupId":"OG001","value":"3.7","lowerLimit":"3.6","upperLimit":"3.9"}]}]},{"title":"Sero- at Month 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"347"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"402.6","lowerLimit":"359.7","upperLimit":"450.6"},{"groupId":"OG001","value":"3.7","lowerLimit":"3.6","upperLimit":"3.8"}]}]},{"title":"Sero- at Month 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"358"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"321.7","lowerLimit":"286.9","upperLimit":"360.7"},{"groupId":"OG001","value":"3.7","lowerLimit":"3.6","upperLimit":"3.9"}]}]},{"title":"Sero- at Month 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"245.9","lowerLimit":"218.5","upperLimit":"276.8"},{"groupId":"OG001","value":"3.7","lowerLimit":"3.6","upperLimit":"3.8"}]}]},{"title":"Sero- at Month 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"320"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"228.5","lowerLimit":"201.9","upperLimit":"258.7"},{"groupId":"OG001","value":"3.7","lowerLimit":"3.6","upperLimit":"3.8"}]}]},{"title":"Sero- at Month 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"246"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"174.3","lowerLimit":"151.2","upperLimit":"200.8"},{"groupId":"OG001","value":"3.8","lowerLimit":"3.6","upperLimit":"4.0"}]}]},{"title":"Sero- at Month 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"254"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"177.7","lowerLimit":"154.1","upperLimit":"204.8"},{"groupId":"OG001","value":"9.2","lowerLimit":"9.0","upperLimit":"9.5"}]}]},{"title":"Sero- at Month 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"166.2","lowerLimit":"143.4","upperLimit":"192.7"},{"groupId":"OG001","value":"9.1","lowerLimit":"9.0","upperLimit":"9.3"}]}]},{"title":"Sero+ before vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","lowerLimit":"19.9","upperLimit":"26.7"},{"groupId":"OG001","value":"24.2","lowerLimit":"20.6","upperLimit":"28.4"}]}]},{"title":"Sero+ at Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"161"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2933.9","lowerLimit":"2557.1","upperLimit":"3366.3"},{"groupId":"OG001","value":"21.9","lowerLimit":"18.1","upperLimit":"26.5"}]}]},{"title":"Sero+ at Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"936.2","lowerLimit":"796.4","upperLimit":"1100.4"},{"groupId":"OG001","value":"23.6","lowerLimit":"19.4","upperLimit":"28.7"}]}]},{"title":"Sero+ at Month 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"661.3","lowerLimit":"560.9","upperLimit":"779.7"},{"groupId":"OG001","value":"19.5","lowerLimit":"15.7","upperLimit":"24.2"}]}]},{"title":"Sero+ at Month 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"573.6","lowerLimit":"487.7","upperLimit":"674.6"},{"groupId":"OG001","value":"16.6","lowerLimit":"13.5","upperLimit":"20.5"}]}]},{"title":"Sero+ at Month 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"423.1","lowerLimit":"357.9","upperLimit":"500.1"},{"groupId":"OG001","value":"16.4","lowerLimit":"12.9","upperLimit":"20.7"}]}]},{"title":"Sero+ at Month 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"392.3","lowerLimit":"328.9","upperLimit":"468.0"},{"groupId":"OG001","value":"15.9","lowerLimit":"12.7","upperLimit":"19.9"}]}]},{"title":"Sero+ at Month 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"91"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"306.0","lowerLimit":"245.7","upperLimit":"380.9"},{"groupId":"OG001","value":"12.9","lowerLimit":"9.8","upperLimit":"16.9"}]}]},{"title":"Sero+ at Month 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"99"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"324.8","lowerLimit":"264.3","upperLimit":"399.1"},{"groupId":"OG001","value":"16.2","lowerLimit":"13.3","upperLimit":"19.6"}]}]},{"title":"Sero+ at Month 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"98"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"302.2","lowerLimit":"243.4","upperLimit":"375.2"},{"groupId":"OG001","value":"16.5","lowerLimit":"13.4","upperLimit":"20.4"}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted Subjects Against HPV-16 and HPV-18 Viral Neutralization in a Selected Subset of Subjects.","description":"Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. HPV-16/18 assay cut-off value was defined as greater than or equal to 40 Estimated dose 50% (ED50). Sero- subjects are subjects who had an antibody concentration below 40 ED50 prior to vaccination. Sero+ subjects are subjects who had an antibody concentration equal to or above 50 ED50 prior to vaccination. ED50 = the estimated serum dilution reducing the signal generated by viral infection by 50%","populationDescription":"The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Prior to vaccination and at Months 7, 12, 18, 24, 48 and 84.","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}]}],"classes":[{"title":"HPV-16 sero- [pre-vaccination]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 sero- [at Month 7]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 sero- [at Month 12]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 sero- [at Month 18]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 sero- [at Month 24]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-16 sero- [at Month 48]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 sero- [at Month 84]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 sero+ [pre-vaccination]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 sero+ [at Month 7]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 sero+ [at Month 12]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 sero+ [at Month 18]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 sero+ [at Month 24]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 sero+ [at Month 48]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 sero+ [at Month 84]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-18 sero- [pre-vaccination]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 sero- [at Month 7]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 sero- [at Month 12]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 sero- [at Month 18]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 sero- [at Month 24]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-18 sero- [at Month 48]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 sero- [at Month 84]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 sero+ [pre-vaccination]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-18 sero+ [at Month 7]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-18 sero+ [at Month 12]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-18 sero+ [at Month 18]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-18 sero+ [at Month 24]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-18 sero+ [at Month 48]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-18 sero+ [at Month 84]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) Against HPV-16 and HPV-18 Viral Neutralization Antibodies in a Selected Subset of Subjects.","description":"Titers are expressed as geometric mean antibody titers (GMTs).\n\nSeronegative (Sero-) subjects are subjects who had an antibody titer below 40 ED50 prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody titer equal to or above 40 ED50 prior to vaccination.\n\nED50 = Estimated dose 50%, the estimated serum dilution reducing the signal generated by viral infection by 50%","populationDescription":"The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Prior to vaccination and at Months 7, 12, 18, 24, 48 and 84.","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}]}],"classes":[{"title":"HPV-16 sero- [pre-vaccination]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-16 sero- [at Month 7]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11663.5","lowerLimit":"7507.2","upperLimit":"18120.8"},{"groupId":"OG001","value":"20.8","lowerLimit":"19.2","upperLimit":"22.4"}]}]},{"title":"HPV-16 sero- [at Month 12]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5597.7","lowerLimit":"3688.3","upperLimit":"8495.6"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-16 sero- [at Month 18]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2175.2","lowerLimit":"1390.8","upperLimit":"3401.9"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-16 sero- [at Month 24]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1941.7","lowerLimit":"1193.0","upperLimit":"3160.4"},{"groupId":"OG001","value":"22.3","lowerLimit":"18.6","upperLimit":"26.6"}]}]},{"title":"HPV-16 sero- [at Month 48]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"828.9","lowerLimit":"488.4","upperLimit":"1406.7"},{"groupId":"OG001","value":"21.4","lowerLimit":"18.7","upperLimit":"24.5"}]}]},{"title":"HPV-16 sero- [at Month 84]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1213.4","lowerLimit":"1213.4","upperLimit":"2779.1"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-16 sero+ [pre-vaccination]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"139.3","lowerLimit":"32.7","upperLimit":"594.2"},{"groupId":"OG001","value":"45.0","lowerLimit":"NA","upperLimit":"NA","comment":"Data were not calculable because of too few subjects."}]}]},{"title":"HPV-16 sero+ [at Month 7]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20283.2","lowerLimit":"2428.3","upperLimit":"169422.0"},{"groupId":"OG001","value":"107.0","lowerLimit":"NA","upperLimit":"NA","comment":"Data were not calculable because of too few subjects."}]}]},{"title":"HPV-16 sero+ [at Month 12]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19484.3","lowerLimit":"7049.3","upperLimit":"53854.2"},{"groupId":"OG001","value":"99.0","lowerLimit":"NA","upperLimit":"NA","comment":"Data were not calculable because of too few subjects."}]}]},{"title":"HPV-16 sero+ [at Month 18]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4393.3","lowerLimit":"798.4","upperLimit":"24175.0"},{"groupId":"OG001","value":"93.0","lowerLimit":"NA","upperLimit":"NA","comment":"Data were not calculable because of too few subjects."}]}]},{"title":"HPV-16 sero+ [at Month 24]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9459.1","lowerLimit":"2168.4","upperLimit":"41263.7"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-16 sero+ [at Month 48]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4187.2","lowerLimit":"676.4","upperLimit":"25921.6"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-16 sero+ [at Month 84]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5837.0","lowerLimit":"5837.0","upperLimit":"35354.6"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-18 sero- [pre-vaccination]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-18 sero- [at Month 7]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7959.6","lowerLimit":"4648.0","upperLimit":"13630.7"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-18 sero- [at Month 12]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1979.9","lowerLimit":"1201.6","upperLimit":"3262.5"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-18 sero- [at Month 18]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1334.6","lowerLimit":"793.3","upperLimit":"2245.3"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-18 sero- [at Month 24]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"826.6","lowerLimit":"493.6","upperLimit":"1384.1"},{"groupId":"OG001","value":"21.4","lowerLimit":"18.7","upperLimit":"24.5"}]}]},{"title":"HPV-18 sero- [at Month 48]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"386.1","lowerLimit":"203.9","upperLimit":"731.1"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-18 sero- [at Month 84]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"491.2","lowerLimit":"232.9","upperLimit":"1036.0"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value."}]}]},{"title":"HPV-18 sero+ [pre-vaccination]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.7","lowerLimit":"9.2","upperLimit":"782.4"},{"groupId":"OG001","value":"115.5","lowerLimit":"21.5","upperLimit":"621.0"}]}]},{"title":"HPV-18 sero+ [at Month 7]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3014.5","lowerLimit":"446.3","upperLimit":"20361.5"},{"groupId":"OG001","value":"163.4","lowerLimit":"0.8","upperLimit":"31959.2"}]}]},{"title":"HPV-18 sero+ [at Month 12]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3377.8","lowerLimit":"2563.9","upperLimit":"4450.1"},{"groupId":"OG001","value":"167.3","lowerLimit":"0.8","upperLimit":"35164.4"}]}]},{"title":"HPV-18 sero+ [at Month 18]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3125.8","lowerLimit":"595.8","upperLimit":"16398.4"},{"groupId":"OG001","value":"254.9","lowerLimit":"0.4","upperLimit":"172814.0"}]}]},{"title":"HPV-18 sero+ [at Month 24]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2493.0","lowerLimit":"261.2","upperLimit":"23793.7"},{"groupId":"OG001","value":"154.9","lowerLimit":"0.4","upperLimit":"53341.9"}]}]},{"title":"HPV-18 sero+ [at Month 48]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"545.0","lowerLimit":"NA","upperLimit":"NA","comment":"Data were not calculable because of too few subjects."},{"groupId":"OG001","value":"86.0","lowerLimit":"0.0","upperLimit":"9662500000"}]}]},{"title":"HPV-18 sero+ [at Month 84]","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Data were not calculable because of too few subjects."},{"groupId":"OG001","value":"968.0","lowerLimit":"NA","upperLimit":"NA","comment":"Data were not calculable because of too few subjects."}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.","description":"Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented and symptom sheets completed.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 7 days (Days 0-6) after vaccination","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2830"},{"groupId":"OG001","value":"2831"}]}],"classes":[{"title":"Any pain","categories":[{"measurements":[{"groupId":"OG000","value":"2411"},{"groupId":"OG001","value":"1862"}]}]},{"title":"Grade 3 pain","categories":[{"measurements":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"73"}]}]},{"title":"Any redness","categories":[{"measurements":[{"groupId":"OG000","value":"1058"},{"groupId":"OG001","value":"530"}]}]},{"title":"Grade 3 redness","categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"5"}]}]},{"title":"Any swelling","categories":[{"measurements":[{"groupId":"OG000","value":"1080"},{"groupId":"OG001","value":"428"}]}]},{"title":"Grade 3 swelling","categories":[{"measurements":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.","description":"Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = axillary temperature above 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = axillary temperature above 39.0°C.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented and symptom sheets completed.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 7 days (Days 0-6) after vaccination","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2832"},{"groupId":"OG001","value":"2832"}]}],"classes":[{"title":"Any arthralgia","categories":[{"measurements":[{"groupId":"OG000","value":"580"},{"groupId":"OG001","value":"439"}]}]},{"title":"Grade3 arthralgia","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"24"}]}]},{"title":"Related arthralgia","categories":[{"measurements":[{"groupId":"OG000","value":"323"},{"groupId":"OG001","value":"225"}]}]},{"title":"Any fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"1116"},{"groupId":"OG001","value":"916"}]}]},{"title":"Grade 3 fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"53"}]}]},{"title":"Related fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"678"},{"groupId":"OG001","value":"545"}]}]},{"title":"Any fever","categories":[{"measurements":[{"groupId":"OG000","value":"308"},{"groupId":"OG001","value":"248"}]}]},{"title":"Grade 3 fever","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"8"}]}]},{"title":"Related fever","categories":[{"measurements":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"159"}]}]},{"title":"Any gastrointestinal","categories":[{"measurements":[{"groupId":"OG000","value":"664"},{"groupId":"OG001","value":"592"}]}]},{"title":"Grade 3 gastrointestinal","categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"54"}]}]},{"title":"Related gastrointestinal","categories":[{"measurements":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"312"}]}]},{"title":"Any headache","categories":[{"measurements":[{"groupId":"OG000","value":"1165"},{"groupId":"OG001","value":"1074"}]}]},{"title":"Grade 3 headache","categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"}]}]},{"title":"Related headache","categories":[{"measurements":[{"groupId":"OG000","value":"666"},{"groupId":"OG001","value":"598"}]}]},{"title":"Any myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"878"},{"groupId":"OG001","value":"622"}]}]},{"title":"Grade 3 myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"32"}]}]},{"title":"Related myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"541"},{"groupId":"OG001","value":"391"}]}]},{"title":"Any rash","categories":[{"measurements":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"124"}]}]},{"title":"Grade 3 rash","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}]},{"title":"Related rash","categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"61"}]}]},{"title":"Any urticaria","categories":[{"measurements":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"201"}]}]},{"title":"Grade 3 urticaria","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"}]}]},{"title":"Related urticaria","categories":[{"measurements":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).","description":"An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 unsolicited AE = an event that prevented normal activity.\n\nA related AE = event assessed by the investigator as causally related to the study vaccination.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 30 days (Days 0 - 29) post-vaccination period.","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2877"},{"groupId":"OG001","value":"2870"}]}],"classes":[{"title":"Any AEs","categories":[{"measurements":[{"groupId":"OG000","value":"1153"},{"groupId":"OG001","value":"1164"}]}]},{"title":"Grade 3 AEs","categories":[{"measurements":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"184"}]}]},{"title":"Related AEs","categories":[{"measurements":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"191"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).","description":"SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. A related SAE was defined as an event assessed by the investigator as causally related to the study vaccination.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48 and up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2877"},{"groupId":"OG001","value":"2870"}]}],"classes":[{"title":"Any SAEs, M48","categories":[{"measurements":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"266"}]}]},{"title":"Related SAEs, M48","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}]}]},{"title":"Any SAEs, M84","categories":[{"measurements":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"269"}]}]},{"title":"Related SAEs, M84","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Related or Fatal Serious Adverse Event.","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2877"},{"groupId":"OG001","value":"2870"}]}],"classes":[{"title":"Fatal AEs","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}]},{"title":"Related SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study.","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\n\nSerious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2877"},{"groupId":"OG001","value":"2870"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"14"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting New Onset of Chronic Disease (NOCDs).","description":"NOCDs include autoimmune disorders, asthma and type I diabetes.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2877"},{"groupId":"OG001","value":"2870"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"165"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting New Onset of Autoimmune Disease (NOADs).","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2877"},{"groupId":"OG001","value":"2870"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Medically Significant Conditions (MAEs).","description":"Medically significant conditions were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2877"},{"groupId":"OG001","value":"2870"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1170"},{"groupId":"OG001","value":"1140"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Pregnancies and Their Outcomes.","description":"Pregnancy outcomes are live infant, premature live infant, elective termination, ectopic pregnancy, spontaneous abortion, lost to follow-up and pregnancy ongoing. For each category it was specified if the infant presents congenital anomaly (CA) or no apparent congenital anomaly (No ACA).","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"357"}]}],"classes":[{"title":"Live infant No ACA, M48","categories":[{"measurements":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"249"}]}]},{"title":"Live infant CA, M48","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}]}]},{"title":"Elective termination No ACA, M48","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"24"}]}]},{"title":"Elective termination CA, M48","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Ectopic pregnancy, M48","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}]},{"title":"Spontaneous abortion No ACA, M48","categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"}]}]},{"title":"Spontaneous abortion CA, M48","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Stillbirth No ACA, M48","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Lost to follow-up, M48","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the Type Assignment Algorithm (TAA)","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nDetection was done on subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.\n\nTAA: Type assignment algorithm. The lesion was assigned to an HPV type found in the lesion if\n\n1. the same HPV type was found in at least one of the two (closest) preceding cytology samples, or\n2. none of the HPV types found in the lesion were found in any of the two preceding cytology samples (isolate HPV types)","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"classes":[{"title":"HPV-16/18 DNA-","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2224"},{"groupId":"OG001","value":"2190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-16 DNA-","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2167"},{"groupId":"OG001","value":"2131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-18 DNA-","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2203"},{"groupId":"OG001","value":"2165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done in: - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2124"},{"groupId":"OG001","value":"2109"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1815"},{"groupId":"OG001","value":"1786"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"67"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1482"},{"groupId":"OG001","value":"1466"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"51"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1535"},{"groupId":"OG001","value":"1511"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"17"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"851"},{"groupId":"OG001","value":"837"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"574"},{"groupId":"OG001","value":"573"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"541"},{"groupId":"OG001","value":"534"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2124"},{"groupId":"OG001","value":"2109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"82"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2073"},{"groupId":"OG001","value":"2055"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"60"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2108"},{"groupId":"OG001","value":"2085"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"23"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals). - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2093"},{"groupId":"OG001","value":"2081"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1789"},{"groupId":"OG001","value":"1764"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"37"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1464"},{"groupId":"OG001","value":"1447"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"27"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1513"},{"groupId":"OG001","value":"1494"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"835"},{"groupId":"OG001","value":"825"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"567"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"532"},{"groupId":"OG001","value":"523"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2093"},{"groupId":"OG001","value":"2081"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"43"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2043"},{"groupId":"OG001","value":"2030"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"30"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2077"},{"groupId":"OG001","value":"2057"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.","description":"Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2125"},{"groupId":"OG001","value":"2111"}]}],"classes":[{"title":"HPV-16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2073"},{"groupId":"OG001","value":"2055"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"60"}]}]},{"title":"HPV-18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2108"},{"groupId":"OG001","value":"2085"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"23"}]}]},{"title":"HPV-31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2073"},{"groupId":"OG001","value":"2090"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"29"}]}]},{"title":"HPV-33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2105"},{"groupId":"OG001","value":"2094"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2112"},{"groupId":"OG001","value":"2101"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"17"}]}]},{"title":"HPV-39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2097"},{"groupId":"OG001","value":"2078"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"26"}]}]},{"title":"HPV-45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2106"},{"groupId":"OG001","value":"2088"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"30"}]}]},{"title":"HPV-51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2071"},{"groupId":"OG001","value":"2072"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"42"}]}]},{"title":"HPV-52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2060"},{"groupId":"OG001","value":"2058"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"56"}]}]},{"title":"HPV-56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2100"},{"groupId":"OG001","value":"2081"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"30"}]}]},{"title":"HPV-58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2098"},{"groupId":"OG001","value":"2092"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"19"}]}]},{"title":"HPV-59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2105"},{"groupId":"OG001","value":"2083"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"}]}]},{"title":"HPV-66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2089"},{"groupId":"OG001","value":"2080"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"49"}]}]},{"title":"HPV-68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2084"},{"groupId":"OG001","value":"2085"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"33"}]}]},{"title":"HPV-31/45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2121"},{"groupId":"OG001","value":"2109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"57"}]}]},{"title":"HPV-31/45/33/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2125"},{"groupId":"OG001","value":"2111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"128"}]}]},{"title":"HPV-39/45/59/68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2125"},{"groupId":"OG001","value":"2111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"102"}]}]},{"title":"HPV-31/33/35/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2125"},{"groupId":"OG001","value":"2111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"118"}]}]},{"title":"HPV-31/45/33/52/58/35/39/51/56/59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2125"},{"groupId":"OG001","value":"2111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"220"}]}]},{"title":"HPV-HRW","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2125"},{"groupId":"OG001","value":"2111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"274"}]}]},{"title":"HPV-HR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2125"},{"groupId":"OG001","value":"2111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"330"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. subjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"2083"}]}],"classes":[{"title":"HPV-16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2043"},{"groupId":"OG001","value":"2030"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"30"}]}]},{"title":"HPV-18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2077"},{"groupId":"OG001","value":"2057"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}]}]},{"title":"HPV-31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2044"},{"groupId":"OG001","value":"2062"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"17"}]}]},{"title":"HPV-33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2074"},{"groupId":"OG001","value":"2068"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}]}]},{"title":"HPV-35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2081"},{"groupId":"OG001","value":"2073"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2067"},{"groupId":"OG001","value":"2050"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2076"},{"groupId":"OG001","value":"2060"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"13"}]}]},{"title":"HPV-51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2040"},{"groupId":"OG001","value":"2045"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"26"}]}]},{"title":"HPV-52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2029"},{"groupId":"OG001","value":"2031"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"31"}]}]},{"title":"HPV-56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2071"},{"groupId":"OG001","value":"2054"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"15"}]}]},{"title":"HPV-58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2067"},{"groupId":"OG001","value":"2065"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"}]}]},{"title":"HPV-59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2074"},{"groupId":"OG001","value":"2055"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2058"},{"groupId":"OG001","value":"2052"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}]}]},{"title":"HPV-68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2053"},{"groupId":"OG001","value":"2057"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"22"}]}]},{"title":"HPV-31/45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2091"},{"groupId":"OG001","value":"2081"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"28"}]}]},{"title":"HPV-31/45/33/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"2083"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"75"}]}]},{"title":"HPV-39/45/59/68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"2083"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"54"}]}]},{"title":"HPV-31/33/35/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"2083"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"72"}]}]},{"title":"HPV-31/45/33/52/58/35/39/51/56/59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"2083"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"129"}]}]},{"title":"HPV-HRW","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"2083"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"160"}]}]},{"title":"HPV-HR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"2083"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"194"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Note: Results for seropositive status were not analysed.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2146"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1852"},{"groupId":"OG001","value":"1818"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1507"},{"groupId":"OG001","value":"1491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1565"},{"groupId":"OG001","value":"1541"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2112"},{"groupId":"OG001","value":"2090"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2149"},{"groupId":"OG001","value":"2122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2146"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1852"},{"groupId":"OG001","value":"1818"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1507"},{"groupId":"OG001","value":"1491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1565"},{"groupId":"OG001","value":"1541"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-16/18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"870"},{"groupId":"OG001","value":"848"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-16, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"588"},{"groupId":"OG001","value":"583"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-18, DNA- and sero+ subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"552"},{"groupId":"OG001","value":"539"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"16"}]}]},{"title":"HPV-16, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2112"},{"groupId":"OG001","value":"2090"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2149"},{"groupId":"OG001","value":"2122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2733"},{"groupId":"OG001","value":"2735"}]}],"classes":[{"title":"HPV-16/18","categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"66"}]}]},{"title":"HPV-16","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"49"}]}]},{"title":"HPV-18","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status","description":"CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA status.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2733"},{"groupId":"OG001","value":"2735"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"229"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection","description":"Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US). Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Results for seropositive status were not analysed.","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2146"}]}],"classes":[{"title":"HPV-16/18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1852"},{"groupId":"OG001","value":"1818"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"47"}]}]},{"title":"HPV-16, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1507"},{"groupId":"OG001","value":"1491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"34"}]}]},{"title":"HPV-18, DNA- and sero- subjects","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1565"},{"groupId":"OG001","value":"1541"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"14"}]}]},{"title":"HPV-16/18, overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2168"},{"groupId":"OG001","value":"2146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"56"}]}]},{"title":"HPV-16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2112"},{"groupId":"OG001","value":"2090"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"38"}]}]},{"title":"HPV-18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2149"},{"groupId":"OG001","value":"2122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"19"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68","populationDescription":"The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 48","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"2148"}]}],"classes":[{"title":"HPV-16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2112"},{"groupId":"OG001","value":"2090"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"38"}]}]},{"title":"HPV-18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2149"},{"groupId":"OG001","value":"2122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"19"}]}]},{"title":"HPV-31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2117"},{"groupId":"OG001","value":"2127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"23"}]}]},{"title":"HPV-33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2149"},{"groupId":"OG001","value":"2130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2156"},{"groupId":"OG001","value":"2137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"13"}]}]},{"title":"HPV-39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2141"},{"groupId":"OG001","value":"2114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"23"}]}]},{"title":"HPV-45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2150"},{"groupId":"OG001","value":"2125"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"23"}]}]},{"title":"HPV-51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2115"},{"groupId":"OG001","value":"2107"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"34"}]}]},{"title":"HPV-52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2103"},{"groupId":"OG001","value":"2095"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"22"}]}]},{"title":"HPV-56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2114"},{"groupId":"OG001","value":"2115"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"28"}]}]},{"title":"HPV-58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2142"},{"groupId":"OG001","value":"2128"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"13"}]}]},{"title":"HPV-59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2147"},{"groupId":"OG001","value":"2120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"22"}]}]},{"title":"HPV-66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2133"},{"groupId":"OG001","value":"2117"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"43"}]}]},{"title":"HPV-68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2128"},{"groupId":"OG001","value":"2120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}]}]},{"title":"HPV-31/45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2165"},{"groupId":"OG001","value":"2146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"44"}]}]},{"title":"HPV-31/45/33/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"2148"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"78"}]}]},{"title":"HPV-39/45/59/68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"2148"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"74"}]}]},{"title":"HPV-31/33/35/52/58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"2148"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"70"}]}]},{"title":"HPV-31/45/33/52/58/35/39/51/56/59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"2148"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"160"}]}]},{"title":"HPV-HRW","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"2148"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"192"}]}]},{"title":"HPV-HR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"2148"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"223"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy","description":"Detection was done on all subjects irrespective of their baseline HPV DNA status.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2733"},{"groupId":"OG001","value":"2735"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"110"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With First Colposcopy","description":"Detection was done on all subjects irrespective of their baseline HPV DNA status.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2734"},{"groupId":"OG001","value":"2736"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"506"},{"groupId":"OG001","value":"560"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2768"},{"groupId":"OG001","value":"2778"}]}],"classes":[{"title":"HPV-16/18","categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"209"}]}]},{"title":"HPV-16","categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"152"}]}]},{"title":"HPV-18","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"71"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).","description":"Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus. The lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)","populationDescription":"The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 84","groups":[{"id":"OG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."},{"id":"OG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2768"},{"groupId":"OG001","value":"2778"}]}],"classes":[{"title":"HPV-16/18","categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"206"}]}]},{"title":"HPV-16","categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"151"}]}]},{"title":"HPV-18","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"68"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"SAEs: from the beginning of the study up to Month 84. Unsolicited AEs: within 30 days (Days 0-29) post-vaccination period). Solicited AEs: During the 7-day (Days 0-6) post-vaccination period.","eventGroups":[{"id":"EG000","title":"Cervarix Group","description":"Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.","seriousNumAffected":291,"seriousNumAtRisk":2881,"otherNumAffected":2543,"otherNumAtRisk":2881},{"id":"EG001","title":"Aluminium Hydroxide Group","description":"Subjects received 3 doses of Aluminium Hydroxide \\[Al(OH)3\\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.","seriousNumAffected":269,"seriousNumAtRisk":2871,"otherNumAffected":2236,"otherNumAtRisk":2871}],"seriousEvents":[{"term":"Abortion spontaneous complete","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":2881},{"groupId":"EG001","numAffected":16,"numAtRisk":2871}]},{"term":"Abortion spontaneous incomplete","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":2881},{"groupId":"EG001","numAffected":13,"numAtRisk":2871}]},{"term":"Appendicitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":2881},{"groupId":"EG001","numAffected":12,"numAtRisk":2871}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":2881},{"groupId":"EG001","numAffected":12,"numAtRisk":2871}]},{"term":"Uterine leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":2881},{"groupId":"EG001","numAffected":9,"numAtRisk":2871}]},{"term":"Abortion missed","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":2881},{"groupId":"EG001","numAffected":11,"numAtRisk":2871}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":2881},{"groupId":"EG001","numAffected":9,"numAtRisk":2871}]},{"term":"Blighted ovum","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":2881},{"groupId":"EG001","numAffected":7,"numAtRisk":2871}]},{"term":"Abortion threatened","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":2881},{"groupId":"EG001","numAffected":7,"numAtRisk":2871}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":2881},{"groupId":"EG001","numAffected":6,"numAtRisk":2871}]},{"term":"Dengue fever","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pre-eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2881},{"groupId":"EG001","numAffected":5,"numAtRisk":2871}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Uterine polyp","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Cholecystitis chronic","organSystem":"Hepatobiliary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Menorrhagia","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":4,"numAtRisk":2871}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Premature labour","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Calculus ureteric","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Depression","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Dysfunctional uterine bleeding","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Endometriosis","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Ligament rupture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Ovarian adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Pneumonia","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Ruptured ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Arrested labour","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Bartholin's cyst","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Bronchitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Diarrhoea infectious","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Gestational hypertension","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Goitre","organSystem":"Endocrine disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Salpingitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Intraductal proliferative breast lesion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Migraine","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Convulsion","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":4,"numAtRisk":2871}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Obesity","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":3,"numAtRisk":2871}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Asthmatic crisis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Major depression","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Meniscus injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Ovarian cyst torsion","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Premature delivery","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Sinusitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Thyroid neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Abortion complete","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Abortion induced","organSystem":"Surgical and medical procedures","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Addison's disease","organSystem":"Endocrine disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Adenocarcinoma of the cervix","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Adenoma benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Adenomyosis","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Adnexal torsion","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Alcohol poisoning","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Amniotic cavity infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Anaesthetic complication pulmonary","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Anaplastic astrocytoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Angle closure glaucoma","organSystem":"Eye disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Anorexia nervosa","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Arthritis reactive","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Atypical pneumonia","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Autoimmune thyroiditis","organSystem":"Endocrine disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Bartholinitis","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Basal ganglia haemorrhage","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Basedow's disease","organSystem":"Endocrine disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Bone fissure","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Brain contusion","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Breast cancer female","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Breast cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Breast cancer stage II","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Bronchogenic cyst","organSystem":"Congenital, familial and genetic disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Burn infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Calculus bladder","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Cardiac valve disease","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Cellulitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Cerebral cyst","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Cervix cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Chest pain","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Chlamydial infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Cholesterosis","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Chronic gastritis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Chronic myeloid leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Chronic tonsillitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Colitis ulcerative","organSystem":"Immune system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Colpocele","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Conversion disorder","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Costochondritis","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Cyst","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Cystitis klebsiella","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Depression suicidal","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Diabetic coma","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Endometrial hyperplasia","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Endosalpingiosis","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Epiploic appendagitis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Escherichia urinary tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Fibroma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Foetal death","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Foot deformity","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Gastric ulcer perforation","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Gastritis erosive","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Genital prolapse","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Genitourinary tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Glioblastoma multiforme","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Haemorrhage in pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Haemorrhoids thrombosed","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Hepatitis C","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Herpes virus infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Hodgkin's disease","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Homicide","organSystem":"Social circumstances","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Hyperemesis gravidarum","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Hypertensive heart disease","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Ill-defined disorder","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Impaired gastric emptying","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Incarcerated hernia","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Incisional hernia","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Intracranial aneurysm","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Intracranial haematoma","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Joint instability","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Joint range of motion decreased","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Lipoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Liposarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Liver disorder","organSystem":"Hepatobiliary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Lupus-like syndrome","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Lyme disease","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Macular oedema","organSystem":"Eye disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Mediastinum neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Meningioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Menometrorrhagia","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Microcytic anaemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Monoparesis","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Multiple fractures","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Nasal cyst","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Nasal disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Nasopharyngeal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Oedema","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Oedema peripheral","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Oedematous pancreatitis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Opisthorchiasis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Ovarian germ cell teratoma benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Ovarian neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Papillary thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Paronychia","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pasteurella infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Patella fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pelvic abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pelvic inflammatory disease","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pelvic prolapse","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Periostitis","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Peritonsillar abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pilonidal cyst","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pituitary tumour benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Placenta accreta","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Placental transfusion syndrome","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Plasma cell myeloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pneumonia mycoplasmal","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pneumonia streptococcal","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Polycystic ovaries","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Polymyalgia rheumatica","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Post lumbar puncture syndrome","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Post procedural haematoma","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Postpartum haemorrhage","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Premature rupture of membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pyloric stenosis","organSystem":"Congenital, familial and genetic disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pyonephrosis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Pyrexia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Renal abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Renal oncocytoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Retained products of conception","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Retinal vein thrombosis","organSystem":"Eye disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Sarcoidosis","organSystem":"Immune system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Sedation","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Sepsis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Sinus disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Skull fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Splenic infarction","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Stillbirth","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Stress cardiomyopathy","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Synovial cyst","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Synovitis","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Tendon injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Tenosynovitis","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Tension headache","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Teratoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Threatened labour","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Thyroid cyst","organSystem":"Endocrine disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Tibia fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Tooth impacted","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Trigeminal neuralgia","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Tumour haemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Typhoid fever","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Ulnar nerve injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Ureteric obstruction","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Ureteric stenosis","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Urinary retention postoperative","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Uterine atony","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Uterine cyst","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Uterine prolapse","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Uterovaginal prolapse","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Vaginal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Vaginal prolapse","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Vertebral artery dissection","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Vestibular neuronitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Pharyngotonsillitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Postoperative abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":0,"numAtRisk":2871}]},{"term":"Prolonged labour","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2881},{"groupId":"EG001","numAffected":2,"numAtRisk":2871}]},{"term":"Viral infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2881},{"groupId":"EG001","numAffected":1,"numAtRisk":2871}]}],"otherEvents":[{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":203,"numAtRisk":2881},{"groupId":"EG001","numAffected":222,"numAtRisk":2871}]},{"term":"Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2411,"numAtRisk":2881},{"groupId":"EG001","numAffected":1862,"numAtRisk":2871}]},{"term":"Redness","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1058,"numAtRisk":2881},{"groupId":"EG001","numAffected":530,"numAtRisk":2871}]},{"term":"Swelling","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1080,"numAtRisk":2881},{"groupId":"EG001","numAffected":428,"numAtRisk":2871}]},{"term":"Arthralgia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":580,"numAtRisk":2881},{"groupId":"EG001","numAffected":439,"numAtRisk":2871}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1116,"numAtRisk":2881},{"groupId":"EG001","numAffected":916,"numAtRisk":2871}]},{"term":"Fever","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":308,"numAtRisk":2881},{"groupId":"EG001","numAffected":248,"numAtRisk":2871}]},{"term":"Gastrointestinal","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":664,"numAtRisk":2881},{"groupId":"EG001","numAffected":592,"numAtRisk":2871}]},{"term":"Headache","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1165,"numAtRisk":2881},{"groupId":"EG001","numAffected":1074,"numAtRisk":2871}]},{"term":"Myalgia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":878,"numAtRisk":2881},{"groupId":"EG001","numAffected":622,"numAtRisk":2871}]},{"term":"Rash","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":185,"numAtRisk":2881},{"groupId":"EG001","numAffected":124,"numAtRisk":2871}]},{"term":"Urticaria","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":258,"numAtRisk":2881},{"groupId":"EG001","numAffected":201,"numAtRisk":2871}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Belgium"]},"conditionBrowseModule":{"meshes":[{"id":"D030361","term":"Papillomavirus Infections"},{"id":"D002583","term":"Uterine Cervical Neoplasms"}],"ancestors":[{"id":"D015229","term":"Sexually Transmitted Diseases, Viral"},{"id":"D012749","term":"Sexually Transmitted Diseases"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D014412","term":"Tumor Virus Infections"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D014594","term":"Uterine Neoplasms"},{"id":"D005833","term":"Genital Neoplasms, Female"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D002577","term":"Uterine Cervical Diseases"},{"id":"D014591","term":"Uterine Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"}]},"interventionBrowseModule":{"meshes":[{"id":"C510352","term":"human papillomavirus vaccine, L1 type 16, 18"}]}},"hasResults":true}